Persistent URL of this record https://hdl.handle.net/1887/3750398
Documents
-
- Download
- 1-s2.0-S0923753422047810-main
- Publisher's Version
- open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- •
This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing oncogene-addicted mNSCLC.
- •
ESMO-MCBS scores are given to describe the levels of evidence for treatment choices.
- •
ESCAT scores are given to describe the evidence level for genomic alterations as biomarkers for using targeted therapies.
- •
Recommendations are based on available scientific data and the authors’ collective expert opinion.
- •
In clinical practice, all recommendations provided need to be discussed with patients in a shared decision-making approach
- All authors
- Hendriks, L.E.; Kerr, K.M.; Menis, J.; Mok, T.S.; Nestle, U.; Passaro, A.; Peters, S.; Planchard, D.; Smit, E.F.; Solomon, B.J.; Veronesi, G.; Reck, M.; ESMO Guidelines Committee
- Date
- 2023-04-14
- Journal
- Annals of Oncology
- Volume
- 34
- Issue
- 4
- Pages
- 339 - 357